Zai Lab

HKG:9688 · KYG9887T1168

BiotechnologySmall

360

Value44

Profit price72

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price23

Price/Sales35

EV / Gross Profit10

Price/Book23

Quality58

Returns on capital67

Return on Capital68

Cash Return on Capital64

Return on Equity69

Profit margins50

EBIT Margin49

Gross Profitability50

Cash backing58

Accruals50

Owner Earnings Margin66

Growth38

Sales growth1

Profit growth1

Reinvestment51

Price momentum10

Safety38

Debt load44

Debt serviceability22

Refinancing42

Debt Payback1

Liquidity10

Sentiment53

Analyst ratings73

Expectations trend54

Opinion Changes50

Price Target Upside57

Market mood93

Value Creation4/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Zai Lab doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryChina

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2013

Employees307

Websitezailaboratory.com

ISINKYG9887T1168

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

NeurologyChronic DiseasesImmunologyInfectious DiseasesNeuroscienceOncologyPsychiatryCentral Nervous SystemBiotechnologyHealth CarePharmaceutical

Description

Zai Lab Limited, through its wholly owned subsidiaries, is a patient-focused, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. The company is focused on discovering, developi…

Analysis

Middle-of-the-road

Zai Lab Limited sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is tepid; the safety picture is stretched. The company scores 4/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Zai Lab with its peers

Jyong Biotech

NMQ:MENS

—

CountryTaiwan

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Sinovac Biotech

NSQ:SVA

—

CountryChina

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

Clinuvel Pharmaceuticals

ASX:CUV

CountryAustralia

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Mesoblast

ASX:MSB

CountryAustralia

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

PharmaEssentia

TAI:6446

CountryTaiwan

IndustryBiotechnology

SizeMedium

Full Stock Analysis →

PolyNovo

ASX:PNV

CountryAustralia

IndustryHealth Care Equipment & Supplies

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →